DIAN-TU-001 A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer*s Disease
- Conditions
- Alzheimer's diseasealzheimerdementia
- Registration Number
- NL-OMON44417
- Lead Sponsor
- Quintiles
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 15
Know they have an AD-causing mutation OR be unaware of their genetic status and have a 50% chance of having an AD-causing mutation (e.g., parent or biological sibling clinically affected with known AD-causing mutation in family)
* Are within -15 to + 10 years of the estimated age at symptom onset, or, if symptomatic, within 10 years of their age at symptom onset
* CDR 0 to 1, inclusive
* Are able to undergo MRI, LP, PET, and complete all study related testing and evaluations.
Subjects will be excluded if they have a major or unstable illness or are unable to complete all study related testing. Exclusions include implanted metal that cannot be removed for MR scanning, required anticoagulation therapy and pregnancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.